Arbutus Biopharma Corp. (ABUS)
4.33
+0.10
(+2.36%)
USD |
NASDAQ |
Oct 20, 16:00
4.35
+0.02
(+0.46%)
After-Hours: 07:49
Arbutus Biopharma Research and Development Expense (TTM) : 17.80M for June 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 17.80M |
| March 31, 2026 | 20.40M |
| December 31, 2025 | 25.24M |
| September 30, 2025 | 29.04M |
| June 30, 2025 | 37.54M |
| March 31, 2025 | 47.59M |
| December 31, 2024 | 54.04M |
| September 30, 2024 | 62.79M |
| June 30, 2024 | 68.69M |
| March 31, 2024 | 70.83M |
| December 31, 2023 | 73.70M |
| September 30, 2023 | 79.08M |
| June 30, 2023 | 78.97M |
| March 31, 2023 | 84.22M |
| December 31, 2022 | 84.41M |
| September 30, 2022 | 81.90M |
| June 30, 2022 | 78.14M |
| March 31, 2022 | 70.59M |
| December 31, 2021 | 65.50M |
| September 30, 2021 | 59.60M |
| June 30, 2021 | 55.37M |
| March 31, 2021 | 50.44M |
| December 31, 2020 | 47.48M |
| September 30, 2020 | 45.36M |
| June 30, 2020 | 51.03M |
| Date | Value |
|---|---|
| March 31, 2020 | 53.30M |
| December 31, 2019 | 57.60M |
| September 30, 2019 | 56.25M |
| June 30, 2019 | 55.08M |
| March 31, 2019 | 58.70M |
| December 31, 2018 | 57.93M |
| September 30, 2018 | 64.69M |
| June 30, 2018 | 63.66M |
| March 31, 2018 | 62.75M |
| December 31, 2017 | 62.68M |
| September 30, 2017 | 60.51M |
| June 30, 2017 | 59.21M |
| March 31, 2017 | 58.48M |
| December 31, 2016 | 56.55M |
| September 30, 2016 | 54.40M |
| June 30, 2016 | 55.02M |
| March 31, 2016 | 49.59M |
| December 31, 2015 | 47.30M |
| September 30, 2015 | 45.70M |
| June 30, 2015 | 40.16M |
| March 31, 2015 | 40.17M |
| December 31, 2014 | 38.71M |
| September 30, 2014 | 33.78M |
| June 30, 2014 | 29.93M |
| March 31, 2014 | 25.58M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Gossamer Bio, Inc. | 163.94M |
| Legend Biotech Corp. | 397.18M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| Anika Therapeutics, Inc. | 27.45M |